Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT) (HR-GCT)
Primary Purpose
Giant Cell Tumor of Bone, Osteoclastoma
Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Zoledronic acid
Sponsored by
About this trial
This is an interventional treatment trial for Giant Cell Tumor of Bone focused on measuring GCT, Bisfosfonates
Eligibility Criteria
Inclusion Criteria:
- Signed written informed consent
- Male or female > 18 years of age
- Histologically proven GCT treated with surgery
High risk GCT defined as minimal one or more of the following:
- Recurrent GCT
- GCT located in the pelvis, sacrum, spine, distal ulna or growth in soft tissue
- GCT grade III
- Pathological fracture in GCT
- Absence of local adjuvant therapy (cryosurgery or phenol instillation)
- Neutrophils > 1.5x109/L, platelets > 100x109/L, and Hb > 6 mmol/l
- Bilirubin level < 1.5 x ULN
- ASAT and ALAT < 2.5 x ULN
- Adequate renal function as defined by: serum creatinine clearance > 60 cc/min
- Expected adequacy of follow-up
Exclusion Criteria:
- Unresectable or metastatic GCT and grade IV GCT
- Prior bisphosphonate usage, except preoperative treatment with zoledronic acid up to 3 months before surgery
- Other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix
- Known hypersensitivity reaction to any of the components of the treatment
- Pregnancy or lactating
- Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent
Sites / Locations
- University hospital Gent
- Academic Medical Center, University of Amsterdam
- Groningen University Medical Center
- Leiden University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Zoledronic acid
Control
Arm Description
Adjuvant zoledronic acid
Standard care
Outcomes
Primary Outcome Measures
Determine if adjuvant zoledronic acid improves the 2 year recurrence rate of 'high risk' GCT as compared to standard care
Secondary Outcome Measures
Evaluate the usefulness of bone remodelling markers in diagnosing and monitoring GCT
Determine the relapse free survival
Full Information
NCT ID
NCT00889590
First Posted
April 28, 2009
Last Updated
January 25, 2016
Sponsor
Leiden University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00889590
Brief Title
Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)
Acronym
HR-GCT
Official Title
Adjuvant Zoledronic Acid in 'High Risk' Giant Cell Tumour of Bone (GCT) - A Randomized Phase II Study
Study Type
Interventional
2. Study Status
Record Verification Date
January 2016
Overall Recruitment Status
Terminated
Why Stopped
low recruitment with registration denosumab
Study Start Date
December 2008 (undefined)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
July 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Leiden University Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a multicenter, randomised phase II trial in patients with high risk GCT.
Primary objective:
Determine if adjuvant zoledronic acid improves the 2 years recurrence rate of 'high risk' GCT as compared to standard care
Secondary objectives:
Determine the relapse free survival
Evaluate the usefulness of bone remodelling markers in diagnosing and monitoring GCT
Detailed Description
GCT is a potentially malignant tumour that presents with a locally destructive osteolytic lesion. The high risk GCT are characterized by a high recurrence rate around the 40-45%. Zoledronic acid is a potent inhibitor of osteolysis and is capable of inducing osteoclast and stromal cell apoptosis, which makes it an attractive adjuvant treatment in 'high risk' GCT in order to improve clinical outcomes and reduce the recurrence rate.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Giant Cell Tumor of Bone, Osteoclastoma
Keywords
GCT, Bisfosfonates
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Zoledronic acid
Arm Type
Experimental
Arm Description
Adjuvant zoledronic acid
Arm Title
Control
Arm Type
No Intervention
Arm Description
Standard care
Intervention Type
Drug
Intervention Name(s)
Zoledronic acid
Other Intervention Name(s)
Zometa
Intervention Description
4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
Primary Outcome Measure Information:
Title
Determine if adjuvant zoledronic acid improves the 2 year recurrence rate of 'high risk' GCT as compared to standard care
Time Frame
4 years
Secondary Outcome Measure Information:
Title
Evaluate the usefulness of bone remodelling markers in diagnosing and monitoring GCT
Time Frame
4 years
Title
Determine the relapse free survival
Time Frame
4 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signed written informed consent
Male or female > 18 years of age
Histologically proven GCT treated with surgery
High risk GCT defined as minimal one or more of the following:
Recurrent GCT
GCT located in the pelvis, sacrum, spine, distal ulna or growth in soft tissue
GCT grade III
Pathological fracture in GCT
Absence of local adjuvant therapy (cryosurgery or phenol instillation)
Neutrophils > 1.5x109/L, platelets > 100x109/L, and Hb > 6 mmol/l
Bilirubin level < 1.5 x ULN
ASAT and ALAT < 2.5 x ULN
Adequate renal function as defined by: serum creatinine clearance > 60 cc/min
Expected adequacy of follow-up
Exclusion Criteria:
Unresectable or metastatic GCT and grade IV GCT
Prior bisphosphonate usage, except preoperative treatment with zoledronic acid up to 3 months before surgery
Other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix
Known hypersensitivity reaction to any of the components of the treatment
Pregnancy or lactating
Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
J R Kroep, MD PhD
Organizational Affiliation
Leiden University Medical Center (LUMC)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
P D Dijkstra, MD PhD
Organizational Affiliation
LUMC
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
A H Taminiau, MD PhD
Organizational Affiliation
LUMC
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
P C Hogendoorn, MD PhD
Organizational Affiliation
LUMC
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
H Gelderblom, MD PhD
Organizational Affiliation
LUMC
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
N A Hamdy, MD PhD
Organizational Affiliation
LUMC
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
S E Papapoulos, MD PhD
Organizational Affiliation
LUMC
Official's Role
Study Director
Facility Information:
Facility Name
University hospital Gent
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
Academic Medical Center, University of Amsterdam
City
Amsterdam
ZIP/Postal Code
1100DD
Country
Netherlands
Facility Name
Groningen University Medical Center
City
Groningen
ZIP/Postal Code
9700 RB
Country
Netherlands
Facility Name
Leiden University Medical Center
City
Leiden
ZIP/Postal Code
2300RC
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
31040253
Citation
Lipplaa A, Kroep JR, van der Heijden L, Jutte PC, Hogendoorn PCW, Dijkstra S, Gelderblom H. Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial. Oncologist. 2019 Jul;24(7):889-e421. doi: 10.1634/theoncologist.2019-0280. Epub 2019 Apr 30.
Results Reference
derived
Learn more about this trial
Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)
We'll reach out to this number within 24 hrs